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Successful Treatment of a Cervical Ectopic Pregnancy
with Single-Dose Methotrexate Therapy
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ABSTRACT
Ectopic pregnancies implanted in the cervix account for less than one percent of all
extra-uterine pregnancies. Due to the rare incidence of cervical ectopic pregnancies,
there are no established guidelines for medical versus surgical management. We report
a case of a cervical ectopic pregnancy with a fetal heartbeat successfully treated with
single-dose methotrexate therapy.
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INTRODUCTION
An ectopic pregnancy is a pregnancy that is
implanted outside of the uterus, most commonly
within the fallopian tube, but can occur in other
rare sites such as the cervical canal. Cervical ectopic
pregnancies occur in 1 in 9000 pregnancies.1,2 An
ectopic pregnancy implanted in the cervical canal
is considered a non-viable gestation with high risk
for maternal morbidity and mortality. Prior reports
describe multi-dose methotrexate therapy for an
embryo with no fetal pole, and direct potassium
chloride (KCL) injection into the gestational sac if a
heartbeat is present.3 We report a case of a cervical
ectopic pregnancy with a fetal heartbeat successfully
treated with single-dose methotrexate therapy.
CASE DESCRIPTION
A 22-year-old gravida 2 para 0 at 6 weeks and 5
days gestational age by the last menstrual period
presented to the emergency room with heavy vaginal
bleeding. A previous dating and viability transvaginal
ultrasound at her OB/GYN’s office was suspicious for a
cervical ectopic pregnancy. She reported no previous
medical conditions. The patient’s obstetric history
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was significant for a previous dilation and curettage
at 7 weeks and 3 days gestation due to a spontaneous
abortion. She denied any sexually transmitted
infections.
On physical exam, the patient’s abdomen was soft,
non-tender and non-distended. Initial vital signs were
temperature 97.6 F, pulse 77, blood pressure 109/68.
Sterile speculum exam was performed, and clotted
blood was observed protruding from the external
cervical os. Transvaginal ultrasound was performed
and demonstrated an intracervical pregnancy with
a crown-rump length of 6.8 mm, a gestational sac
measuring 9.9 mm, a yolk sac measuring 3.0 mm,
and a fetal heart rate of 113 beats per minute (Figure
1 and Figure 2). A maternal-fetal medicine specialist
was consulted, and the diagnosis of a cervical
ectopic pregnancy was confirmed. The patient’s
left and right ovaries were visualized and appeared
normal with a suspected right corpus luteum cyst.
The initial beta-human chorionic gonadotropin
(HCG) quantitative measurement was 5688 mIU/mL.
The initial hemoglobin/hematocrit (Hgb/Hct) level
was 14.0/42.1 and the patient was typed and crossmatched.
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FIGURE 1: Pregnancy Implanted in the Cervical Canal

After counseling the patient on the
ultrasound and laboratory findings,
routes of administration were
discussed. These included singledose methotrexate, multiple-dose
methotrexate or KCL injection for
a cervical ectopic pregnancy. She
elected to proceed with single-dose
methotrexate therapy. Methotrexate
50 mg/m2 was given to the patient,
for a total dose of 84.5 mg.
One day following methotrexate
administration (post-injection
day 1), cardiac activity was again
demonstrated on ultrasound, and repeat betaHCG quantitative measurement was 5587 mIU/
mL. Following the ultrasound, the patient began
experiencing nausea and then heavy vaginal
bleeding requiring the use of three pads over six
hours. She never became hemodynamically unstable,
and repeat measurement of Hgb/Hct 12.2/36.6 was
reassuring. A transvaginal ultrasound performed the
following morning (post-injection day 2) showed no
evidence of intracervical pregnancy. Her beta-HCG
quantitative measurement decreased to 1856 mIU/
mL. The patient then signed out against medical
advice.
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FIGURE 2: 3D Rendering of Pregnancy Implanted in the
Cervical Canal

DISCUSSION
Cervical ectopic pregnancies account for less than 1
percent of all ectopic pregnancies.4,5 Early diagnosis
and treatment are critical in cervical pregnancies due
to the high risk of maternal morbidity and mortality,
primarily due to severe hemorrhage.6
The most common presenting symptom of a cervical
ectopic pregnancy is vaginal bleeding, which is often
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painless and profuse. The differential diagnosis for
painless vaginal bleeding in early pregnancy includes
ectopic pregnancy, miscarriage, implantation
bleeding, and gestational trophoblastic disease.7
Management is primarily dictated by the patient’s
hemodynamic status. In a stable patient, the
mainstay of diagnosis is transvaginal ultrasound
and physical exam coupled with serial serum
beta HCG levels following treatment. Due to the
rare incidence of cervical ectopic pregnancies,
there are no established guidelines for medical
versus surgical management. Existing literature
from case reports and case series suggests initial
treatment with multi-dose methotrexate therapy
if there is no fetal heartbeat, and direct intraamniotic potassium chloride (KCL) injection if a
fetal heartbeat is present.8 While methotrexate
has a higher chance of failure, intra-amniotic KCL
injection is associated with maternal hemorrhage
when the gestational sac collapses.9 Methotrexate
interferes with DNA synthesis, repair, and cellular
replication by inhibiting DHFR, which depletes the
cellular pools. Some absolute contraindications to
methotrexate therapy are active pulmonary disease,
alcoholism, breastfeeding, hematologic dysfunction,
immunodeficiency syndrome, peptic ulcer disease
and renal disease.10
In fallopian tube ectopic pregnancies, two-dose
methotrexate is recommended if the beta-HCG
quantitative is above 3,000 mIU/mL or if the
mass measures greater than two cm. Multi-dose
methotrexate is another option for cervical ectopic
pregnancies and requires 1mg/kg per day on days 1,
3, 5, and 7 combined with IM leucovorin 0.1 mg/kg
on days 2, 4, 6, and 8. A single dose approach is less
expensive, requires less intensive monitoring and
has fewer adverse effects.11 In this current case, our
patient elected for a more conservative management
with single-dose methotrexate therapy. In light
of the patient’s stable hemodynamic status and
ability to provide inpatient monitoring during and
after treatment with methotrexate, this approach
with methotrexate therapy alone was considered a
reasonable option in this case. An early gestational
age of 6 weeks and 5 days could have contributed
to the success of single-dose methotrexate therapy
in this case. A limitation in this case was that the
beta-HCG levels could not be followed to zero due to
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the patient leaving against medical advice. Repeat
imaging demonstrated resolution of the cervical
ectopic pregnancy, and repeat beta-HCG levels
significantly declined. Serial HCG levels should be
obtained until a nonpregnancy level is achieved,
which may take up to eight weeks. Failure of the HCG
level to decrease by at least 15% from day four to day
seven after methotrexate administration is associated
with treatment failure and additional methotrexate
or surgical intervention may be considered.10
Cervical ectopic pregnancies are uncommon. When
counseling patients regarding their options for
the treatment of cervical ectopic pregnancies, a
shared decision-making model should be employed
when determining how to treat these non-viable
pregnancies. A conservative approach with singledose methotrexate therapy was successful in this
case even though a fetal heartbeat was present on
ultrasound.
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